TRPM2 and ischemic stroke: Intriguingly, TRPM2 has been shown to be the primary mediator of ROS-dependent BBB degradation in several brain disorders (Ding et al., 2021), including ischemic stroke (Zong et al., 2024) and Alzheimer’s disease (Park et al., 2014).